Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

BMC Cancer

Tomas Buchler²  Tomas Pavlik⁶  Bohuslav Melichar³  Zbynek Bortlicek⁶  Zuzana Usiakova⁵  Ladislav Dusek⁶  Igor Kiss⁷  Milan Kohoutek¹  Vera Benesova⁴  Rostislav Vyzula⁷  Jitka Abrahamova²  Radka Obermannova⁷ 

[1] Centre for Oncology, Tomas Bata Hospital, Havlickovo nabrezi 600, Zlin 762 75, Czech Republic

[2] Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, Prague 140 59, Czech Republic

[3] Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P.Pavlova 6, Olomouc 775 20, Czech Republic

[4] Department of Oncology, Jihlava Hospital, Vrchlickeho 59, Jihlava 586 33, Czech Republic

[5] Department of Oncology and First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 128 08, Czech Republic

[6] Institute of Biostatistics and Analyses, Masaryk University, Kamenice 126/3, Brno 625 00, Czech Republic

[7] Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

关键词: Oxaliplatin;    5-fluorouracil;    Capecitabine;    Bevacizumab;    Colorectal cancer;   

Others  :  858835
DOI  :  10.1186/1471-2407-14-323

 received in 2013-04-22, accepted in 2014-04-30,  发布年份 2014

【 摘 要 】

Background

Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC).

Methods

A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis.

Results

No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progression-free survival (PFS) was 11.4 months (95% CI 10.7-12.1 months) for FOLFOX/bevacizumab and 11.5 months (95% CI 10.8-12.3 months) for XELOX/bevacizumab (p = 0.337). The number of metastatic sites was identified as the most significant predictor of PFS and, together with the presence/absence of metastatic disease at diagnosis, also for OS.

Conclusions

According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone chemotherapy regimen.

【 授权许可】

   
2014 Buchler et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
• [2]Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
• [3]Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, Legakis J, Armakolas A: Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010, 78:376-381.
• [4]Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol 2007, 25:1539-1544.
• [5]Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Saltz L: First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 2006, 17(9):LBA3.
• [6]Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008, 26:5910-5917.
• [7]Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
• [8]Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870.
• [9]Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, Schrag D: Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients withstage IV colorectal cancer. J Clin Oncol 2012, 30:608-615.
• [10]Zuckerman DS, Clark JW: Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008, 112:1879-1891.
• [11]Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L: XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011, 105:58-64.